Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H26O3 |
Molecular Weight | 326.4293 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 4 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C)C(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1
InChI
InChIKey=IHUNBGSDBOWDMA-AQFIFDHZSA-N
InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21720660
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21720660
Acitretin is all-Trans-9-(4-methoxy-2, 3, 6¬ trimethylphenyl)-three, 7-dimethyl-2, 4, 6, 8-nonatetraenoic acid. It is a metabolite of exterminate and is related to both retinoic acid and retinol (vitamin A). It is taken orally, and is typically used for psoriasis. The mechanism of action of is unknown. However it is believed to work by targeting specific receptors (retinoid receptors such as RXR and RAR) in the skin, which help normalize the growth cycle of skin cells. Studies on nuclear retinoic acid receptors have shown that acitretin activates all 3 receptor subtypes (RAR-alpha, -beta, and -gamma) without measurable receptor binding; this paradox remains unexplained.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800004586
Curator's Comment: # by Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=10459139 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SORIATANE Approved UseAcitretin Capsules USP are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with their use, Acitretin Capsules USP should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, Acitretin Capsules USP should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS — Acitretin Capsules USP can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
416 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2977392 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACITRETIN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FED |
|
416 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACITRETIN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2249 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2977392 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACITRETIN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2977392 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACITRETIN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FED |
PubMed
Title | Date | PubMed |
---|---|---|
Determination of the aromatic retinoids (etretin and isoetretin) in biological fluids by high-performance liquid chromatography. | 1987 Oct 9 |
|
Acitretin-induced myopathy. | 1996 May |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
[Acitretin induces apoptosis and changes of relative signaling pathway in epidermoid carcinoma cell line A431]. | 2006 Mar |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
SORIATANE (acitretin capsules) should be initiated at 25 to 50 mg per day, given as a single dose with the main meal. Maintenance doses of 25 to 50 mg per day may be given dependent upon an individual patient’s response to initial treatment. Relapses may be treated as outlined for initial therapy.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16610086
Curator's Comment: Acitretin plays an inhibitory role in the tumor cell growth and induces the cell apoptosis in A431 cells. The regulation of the Jak/STAT3 signaling pathway may play an important role in inducing growth inhibition and apoptosis by Acitretin in A431 cells.
A431 (epidermoid carcinoma cell lines) were treated with Acitretin at the concentration of 10(-5)mol/L in different time intervals
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007700
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
NDF-RT |
N0000175607
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
NDF-RT |
N0000007700
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
WHO-ATC |
D05BB02
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
NDF-RT |
N0000007700
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
WHO-VATC |
QD05BB02
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
NDF-RT |
N0000007700
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
NCI_THESAURUS |
C804
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
LIVERTOX |
NBK548784
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
||
|
NDF-RT |
N0000007700
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
50173
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
1011007
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
5284513
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
DB00459
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
16818
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
Acitretin
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
X-94
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL1131
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
5530
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
D017255
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
100000084604
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
m1373
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID6022553
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
78
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
ACITRETIN
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
LCH760E9T7
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
259-474-4
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
7187
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
C985
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
LCH760E9T7
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
7598
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
SUB05240MIG
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY | |||
|
55079-83-9
Created by
admin on Fri Dec 15 15:02:54 GMT 2023 , Edited by admin on Fri Dec 15 15:02:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)